Literature DB >> 31939074

Molecular and clinical profile of type 2 von Willebrand disease in Iran: a thirteen-year experience.

Maryam Rassoulzadegan1, Fereydoun Ala1, Mohammad Jazebi1, Mohammad Said Enayat1, Shadi Tabibian2, Mahmood Shams3, Mehran Bahraini2, Akbar Dorgalaleh4.   

Abstract

Type 2 von Willebrand disease (VWD) is the most common congenital bleeding disorder, with variable bleeding tendency and a complex laboratory phenotype. In the current study, we report the clinical and molecular profile of a large number of Iranian patients with type 2 VWD. All exons, intron-exon boundaries, and untranslated regions were sequenced by Sanger sequencing for direct mutation detection. All identified mutations were confirmed in family members and by relevant bioinformatics studies. A total of 136 patients with type 2 VWD were diagnosed, including 42 (30.9%), 32 (23.6%), 38 (27.9%), and 24 (17.6%) patients with type 2A, type 2B, type 2M, and type 2N, respectively. Epistaxis (49%), gum bleeding (30.2%), ecchymosis (23.2%), and menorrhagia (16.3%) were the most common clinical presentations, while miscarriage (2.3%) and umbilical cord bleeding (0.8%) were the rarest. Thirty mutations were identified within the VWF gene, nine (30%) being novel, with p.Arg1379Cys (n = 20), p.Val1316Met (n = 13), p.Arg1597Trp (n = 13), p.Arg1374Cys (n = 10), p.Ser1506Leu (n = 10), and p.Arg1308Cys (n = 9) the most common. Type 2 VWD is a hemorrhagic disorder with variable bleeding tendency and a heterogeneous molecular basis in patients in Iran.

Entities:  

Keywords:  Clinical manifestations; Diagnosis; Molecular analysis; von Willebrand disease type 2

Year:  2020        PMID: 31939074     DOI: 10.1007/s12185-019-02814-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  22 in total

Review 1.  Impact, diagnosis and treatment of von Willebrand disease.

Authors:  J E Sadler; P M Mannucci; E Berntorp; N Bochkov; V Boulyjenkov; D Ginsburg; D Meyer; I Peake; F Rodeghiero; A Srivastava
Journal:  Thromb Haemost       Date:  2000-08       Impact factor: 5.249

2.  New mutations in exon 28 of the von Willebrand factor gene detected in patients with different types of von Willebrand's disease.

Authors:  P Casaña; F Martínez; S Haya; A Tavares; J A Aznar
Journal:  Haematologica       Date:  2001-04       Impact factor: 9.941

3.  Translational medicine advances in von Willebrand disease.

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

4.  The prevalence of symptomatic von Willebrand disease in primary care practice.

Authors:  M Bowman; W M Hopman; D Rapson; D Lillicrap; P James
Journal:  J Thromb Haemost       Date:  2009-10-23       Impact factor: 5.824

5.  Distribution of blood groups in the Iranian general population.

Authors:  Ehsan Shahverdi; Mostafa Moghaddam; Ali Talebian; Hassan Abolghasemi
Journal:  Immunohematology       Date:  2016-12

6.  Type 2B von Willebrand's disease due to Val1316Met mutation. Heterogeneity in the same sibship.

Authors:  E Rendal; N Penas; B Larrabeiti; A Pérez; A Vale; M F López-Fernández; J Batlle
Journal:  Ann Hematol       Date:  2001-06       Impact factor: 3.673

7.  Pregnancy in women with von Willebrand's disease or factor XI deficiency.

Authors:  R A Kadir; C A Lee; C A Sabin; D Pollard; D L Economides
Journal:  Br J Obstet Gynaecol       Date:  1998-03

8.  Characterisation of mutations and molecular studies of type 2 von Willebrand disease.

Authors:  Firdos Ahmad; Rifat Jan; Meganathan Kannan; Tobias Obser; Md Imtaiyaz Hassan; Florian Oyen; Ulrich Budde; Renu Saxena; Reinhard Schneppenheim
Journal:  Thromb Haemost       Date:  2012-11-22       Impact factor: 5.249

9.  De novo mutation and somatic mosaicism of gene mutation in type 2A, 2B and 2M VWD.

Authors:  Ming-Ching Shen; Ming Chen; Gwo-Chin Ma; Shun-Ping Chang; Ching-Yeh Lin; Bo-Do Lin; Han-Ni Hsieh
Journal:  Thromb J       Date:  2016-10-04

Review 10.  Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders.

Authors:  Giancarlo Castaman; Silvia Linari
Journal:  J Clin Med       Date:  2017-04-10       Impact factor: 4.241

View more
  1 in total

1.  Congenital Combined Bleeding Disorders, a Comprehensive Study of a Large Number of Iranian Patients.

Authors:  Seyed Esmaeil Ahmadi; Mohammad Jazebi; Gholamreza Bahoush; Mohammad Reza Baghaipour; Fereydoun Ala; Shadi Tabibian
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.